DS-8201: Data from P3 DESTINY-Breast04 trial (NCT03734029) for HER2-low, unresectable and/or metastatic breast cancer in 2021 (AstraZeneca) - Oct 24, 2019 - Q3 2019 Results: Data from P2 DESTINY-Gastric01 trial (NCT03329690) for HER2-overexpressing advanced gastric cancer in H1 2020
P2 data • P3 data
|